



# Standard Guide for Detection of Nucleic Acids of the Mycobacterium Tuberculosis Complex and Other Pathogenic Mycobacteria by the Polymerase Chain Reaction Technique<sup>1</sup>

This standard is issued under the fixed designation E 2048; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ε) indicates an editorial change since the last revision or reapproval.

## INTRODUCTION

This guide covers detection of nucleic acids (deoxyribonucleic acid (DNA) or ribonucleic acid (RNA)) of mycobacteria and specific identification of the Mycobacterium tuberculosis complex (MTBC, which includes *M. tuberculosis*, *M. bovis*, *M. microti* and *M. africanum*), *M. avium*, *M. leprae* and *M. intracellulare* nucleic acids by the polymerase chain reaction (PCR) technique.

PCR is a widely known molecular biology procedure that involves the amplification of a piece of DNA by as much as a million-fold over the course of several hours. It is also possible to use PCR to detect RNA by first copying RNA with the enzyme reverse transcriptase to produce a complementary DNA molecule, which is then amplified by PCR; the combined process is known as RT-PCR. The amplified DNA fragments can then be detected, identified and quantitated by classical procedures of biochemistry/molecular biology. As few as only several molecules of DNA in a biological test specimen can be rapidly and accurately identified. PCR is used as a tool in molecular biology laboratories for basic and applied research, in clinical laboratories to aid in the diagnosis of genetic, neoplastic and infectious diseases, and in biotechnology laboratories for the preparation of biotechnology products and to test for contaminants.

Mycobacterium tuberculosis (MTB) is the causative agent of tuberculosis (TB) in humans, and TB is one of the leading causes of human death in the world (**1, 2**)<sup>2</sup>. About one third of the present world's population is infected with MTB (**1**). The definitive test for tuberculosis, isolation and specific identification of MTB in culture, requires several weeks. Microscopic examination of acid-fast smears is rapid, but non-specific and relatively insensitive. The value of using PCR or other DNA/RNA amplification procedures for TB diagnosis is rapidity; clinical specimens can be evaluated within a day. Thus, patient care and treatment can be initiated more rapidly when a specific diagnosis has been determined.

This guide was developed by ASTM in collaboration with DIN (German Institute for Standardization) Subcommittee E3/E9 on Molecular Biological Detection of Mycobacteria, Department for Medical Standards (NAMed). It is recommended that this mycobacteria-specific PCR guide be used in conjunction with ASTM's general PCR Guide E 1873. The combination of the two guides provides recommendations, basic considerations, criteria, and principles that should be employed when developing, utilizing or assessing PCR-specific protocols for the detection of the DNA or RNA of specific mycobacteria.

This guide assumes a basic knowledge of microbiology and molecular biology. It assumes the availability of, and the ability to search the literature for, mycobacteria target-specific PCR protocols.

## 1. Scope

1.1 This guide covers basic considerations, criteria, principles and recommendations that should be helpful when

developing, utilizing, or assessing PCR-specific protocols for the amplification and detection or identification of mycobacterial nucleic acids. This guide is not a specific protocol for the detection of specific mycobacteria. It is intended to provide information that will assist the user in obtaining high quality and reliable data. The guide is closely related to and should be used concurrently with the general PCR Guide E 1873.

1.2 This guide has been developed for use in any molecular biology or biotechnology laboratory. It may be useful for the

<sup>1</sup> This guide is under the jurisdiction of ASTM Committee E-48 on Biotechnology and is the direct responsibility of Subcommittee E48.02 on Characterization and Identification of Biological Systems.

Current edition approved October 10, 1999. Published January 2000.

<sup>2</sup> The boldface numbers in parentheses refer to the list of references at the end of this standard.

detection of mycobacteria in clinical, diagnostic laboratories.

1.3 This guide does not cover details of the various methods such as gel electrophoresis that can be utilized to help identify PCR-amplified mycobacterial nucleic acid sequences, and it does not cover details of instrument calibration.

1.4 This guide does not cover specific variations of the basic PCR or RT-PCR technology (for example, quantitative PCR, multiplex PCR and in situ PCR), and it does not cover details of instrument calibration.

1.5 **Warning**—Laboratory work involving certain clinical specimens and microorganisms can be hazardous to personnel. **Precaution:** Biosafety Level 2 facilities are recommended for potentially hazardous work, and Biosafety Level 3 facilities are required for propagating and manipulating *Mycobacteria tuberculosis* cultures (3). Safety guidelines should be adhered to according to NCCLS M29-T2, I17-P and other recommendations (3).

## 2. Referenced Documents

### 2.1 ASTM Standards:

E 1873 Guide for Detection of Nucleic Acid Sequences by the Polymerase Chain Reaction Technique<sup>3</sup>

### 2.2 NCCLS Standards:<sup>4</sup>

M29-T2 Protection of Laboratory Workers from Infectious Disease Transmitted by Blood, Body Fluids, and Tissue—Second Edition; Tentative Guideline

C24-A2 Statistical Quality Control for Quantitative Measurements: Principles and Definitions; Approved Guideline—Second Edition

MM3-A Molecular Diagnostic Methods for Infectious Diseases; Approved Guideline

## 3. Terminology

3.1 Basic PCR definitions apply according to the general PCR Guide E 1873 (Section 3).

### 3.2 Definitions of Terms Specific to This Standard:

3.2.1 *internal control, n*—in PCR, a control used to assess the amplifiability of the reaction, that is, to determine whether or not PCR inhibitors may be present in the reaction; for example, an internal control can be a synthetic DNA segment that can be added to the sample prior to amplification, that is of similar length and base composition to the target gene sequence, and that contains primer binding regions identical to those of the target sequence.

3.2.2 *restriction enzymes, n*—naturally occurring proteins (also called restriction endonucleases) that are purified from bacteria and that recognize specific nucleic acid sequence patterns (sites) and cleave the nucleic acid at or near that sequence (site).

## 4. Significance and Use

4.1 This guide is intended for use in any laboratory utilizing PCR or RT-PCR to amplify and detect nucleic acid sequences of mycobacteria from a biological preparation and to identify the species of origin.

4.2 The criteria used for the identification and evaluation of the amplification reactions should be administered by an individual trained in the use of molecular biological and microbiological techniques associated with PCR and MTB.

## 5. Background Information about TB, MTB, Other Mycobacteria, and Detection of Mycobacteria by PCR

5.1 The mycobacteria are acid-fast, non-motile, rod-shaped, aerobic bacteria that do not form spores. They contain several species pathogenic to humans. The primary human pathogens are members of the *Mycobacterium tuberculosis* complex (*M. tuberculosis*, *M. bovis*, *M. africanum* and *M. microti*) and *M. leprae*. Other mycobacteria, such as the *M. avium* complex (*M. avium* and *M. intracellulare*) and *M. kansasii*, cause disease in immunocompromised individuals.

5.2 Tuberculosis has been a major public health problem in the world for many centuries, particularly in overcrowded city areas. In the 18th and 19th centuries, TB was responsible for a quarter of all adult human deaths in European cities (4). Several public health measures that finally led to a considerable improvement include the pasteurization of milk, and the antibiotics streptomycin (introduced in 1944) and p-aminosalicylic acid (introduced in 1946) (4). However, the emergence of drug-resistant MTB strains is becoming a serious problem. For this and other reasons, TB is presently on the rise again and is one of the leading infectious causes of death of adult humans in the world.

5.2.1 The isolation of a species from the MTBC is required for the definitive diagnosis of tuberculosis. Routine cultures are time-consuming and can take up to eight weeks. Microscopic examination of acid-fast smears is the most rapid method for the detection of mycobacteria, but it is insensitive and non-specific. Immunological and serological techniques are limited, in general, due to poor sensitivity or specificity, or both (5, 6). Species-specific nucleic acid probes have significantly improved the opportunity for rapid confirmation of culture results for several mycobacterial species (7).

5.3 The *M. avium* complex (MAC) consist of 28 serovars (subspecies) of two distinct species, *M. avium* and *M. intracellulare* (8). The criteria used to distinguish *M. avium* from *M. intracellulare* are now well established (9-11). MAC organisms are ubiquitous in nature and have been isolated from water, soil, plants, and other environmental sources (12). These organisms are of low pathogenicity and frequently colonize healthy individuals without causing disease. Person-to-person transmission is thought to be unlikely, but many investigators believe that pulmonary disease may result from inhalation of infectious environmental aerosols. MAC infections have become increasingly more common in the United States, and *M. avium* is the most common non-tuberculous mycobacterial species associated with human disease. The greatest increase in MAC infections during the past decade has been in AIDS patients for whom MAC has become the third most common opportunistic disease (13). In one report, 98 % of MAC infections in 45 AIDS patients were due to *M. avium*, whereas 40 % of MAC infections in patients without AIDS were due to *M. intracellulare* (14).

5.3.1 The isolation of MAC by culture is required for

<sup>3</sup> Annual Book of ASTM Standards, Vol 11.05.

<sup>4</sup> Available from the National Committee for Clinical Laboratory Standards, 771 E. Lancaster Ave., Villanova, PA 19085.

definitive diagnosis of MAC infection. However, routine cultures are time consuming and can take up to eight weeks for final diagnosis. Additionally, culture does not distinguish between *M. avium* and *M. intracellulare* infection. Several of the therapeutic agents used currently in the treatment of MAC disease have different in vitro activity against *M. avium* and *M. intracellulare* (15). As additional therapeutic agents become available, the ability to distinguish between *M. avium* and *M. intracellulare* may become more important.

5.4 *Mycobacterium leprae*, the causative agent of leprosy, remains a serious health problem worldwide (16). Diagnosis of *M. leprae* infections is a problem due to the fact that this organism cannot be cultured by conventional methods. Classical methods of diagnosis, such as microscopic examination of skin biopsies and antibody testing lack sensitivity and specificity (17). However, PCR can be used for rapid and sensitive diagnosis of *M. leprae* infections.

5.5 PCR has proven to be a useful procedure for the detection of mycobacteria and the specific identification of the species present. Mycobacterial DNA in a clinical sample is typically extracted and amplified, and the PCR product is then identified. Depending on the PCR amplification target employed, the analytic sensitivity of amplification assays ranges from about 1 to 100 mycobacteria (17). Primers used in the PCR amplification from mycobacterial genomes can be either species-specific or genus-specific. PCR-based tests specific for mycobacteria have been shown to improve the rapid diagnosis of tuberculosis and other mycobacteria-caused diseases by allowing the direct detection of mycobacteria in clinical specimens.

5.5.1 Clinical studies have demonstrated that PCR-based assays accurately detect MTB in respiratory specimens (18-22). The specificity of these tests ranges from 95 to 100 %. Furthermore, these MTB-specific tests do not cross-react with other mycobacteria. Clinical specimens that yielded non-tuberculosis mycobacteria when cultured gave negative results when tested by MTB-specific PCR assays. The MTB PCR assays generally exhibit greater than 90 % sensitivity for the subset of clinical specimens that are positive for acid-fast bacilli (AFB) positive by microscopy. These assays exhibit lower sensitivity, ranging from 50 to 75 %, for the subset of clinical specimens that are AFB-negative. The limited sensitivity is attributed to the low organism load in AFB-negative specimens. Because the volume of specimen used to inoculate cultures is usually much greater than the volume tested by PCR, mycobacteria may be delivered to the culture, but not to the PCR reaction.

5.5.2 Clinical studies have shown that PCR assays can detect MAC directly in respiratory specimens and in blood (23-27). Many of these assays can distinguish which of the two MAC species, *M. avium* or *M. intracellulare*, is present in the specimen. The specificity of these tests ranges from 97 to 100 %. Furthermore, these MAC-specific tests do not cross-react with other mycobacteria. Clinical specimens that yielded *M. tuberculosis*, or other non-MAC mycobacteria, when cultured gave negative results when tested by MAC-specific PCR assays. Sensitivity for MAC is generally greater than 90 %.

## 6. Principle of the PCR Method

6.1 See Guide E 1873 (Section 5) for a description of the PCR method.

6.2 In addition to 6.1, the amplification of target sequences takes place in vitro. Procedures for detection of specific amplified products that allow a differentiation to be made between species of the MTBC and ubiquitous mycobacterial species should be used preferentially.

## 7. Target Material

7.1 For general information see Guide E 1873 (Sections 6 and 9).

7.2 In addition to 7.1, for the detection of nucleic acid sequences of the MTBC, immediate transport of the test material to the laboratory is recommended. It is possible that transport periods of >48 h can interfere with the nucleic acid detection.

7.3 Typical biological specimens for the detection of mycobacteria or their nucleic acid sequences include:

7.3.1 *Specimens Used in Biotechnology or Basic Molecular Biology Research Laboratories*—Cultures of mycobacteria, purified preparations of mycobacteria or mycobacterial nucleic acid.

7.3.2 *Specimens Used in Clinical, Diagnostic Laboratories in the Case of Suspected MTB Infection*—Respiratory sample material (for example, sputum, bronchoalveolar lavages), gastric juice, stomach aspirate, urine, sperm and prostatic secretion, puncture exudate, cerebrospinal fluid, bone marrow and biopsy material (tissues).

7.4 Methods currently used for extraction of the target sequence from mycobacteria are:

7.4.1 *Alkaline Lysis*—In the presence of sodium hydroxide and detergent with increased temperature and subsequent neutralization of the reaction mixture.

7.4.2 *Guanidium Isothiocyanate*—Extraction.

7.4.3 *Enzymatic Extraction*—Of nucleic acid using proteinase K plus lysozyme or detergent treatment, or both.

7.4.4 *Mechanical-Physical Pretreatment*—For disruption of the bacterial cells, for example, ultrasound, repeated shock freezing/boiling.

7.4.5 A combination of the procedures described in 7.4.1 to 7.4.4 is possible. Methods used should be tested in the laboratory with respect to their efficiency and reproducibility through the introduction of appropriate control bacteria.

7.5 Substances that inhibit PCR such as heparin, hemoglobin, etc., should be considerably reduced in amount through the extraction procedures used. When extraction procedures do not reduce inhibitors sufficiently, typical methods for reducing the amount of inhibitors, such as solid phase adsorption of the nucleic acids or inhibitors, phenol-chloroform extraction, etc., may be used to remove inhibitors. Purification of the extracted nucleic acids by solid phase adsorption, for example, to silicates or resins, can lead to increased purity, but may also result in considerable losses of nucleic acids. This guide recommends that an internal control nucleic acid sequence be added to each sample to monitor amplification and detect samples that inhibit PCR (28).

## 8. PCR Laboratory Design

8.1 Follow instructions for PCR laboratory design according to Guide E 1873 (Section 7) and NCCLS MM3-A (Section 12).

## 9. Special Equipment/Supplies

9.1 *General*—See the recommendations of Guide E 1873 (Section 8) and NCCLS MM3-A (Section 12).

9.2 In addition to 9.1, equipment that ensures safe disruption of mycobacteria, such as programmed incubators, enclosed sonicators, or the equivalent is needed.

9.3 Nucleic acids from mycobacteria of the MTBC and from clinical specimens containing *M. tuberculosis*, *M. avium* or *M. intracellulare* should be isolated in Biosafety Level 2 (BSL2) or BSL3 laboratories.

## 10. Chemicals and Reagents

10.1 *General*—See the recommendations of Guide E 1873 (Section 9).

10.2 *Mycobacteria PCR Primers*—The selected target DNA sequence should be bounded by nucleic acid sequences specific to mycobacterial DNA; these sequences will serve as primer binding sites. The primer binding sequences shall be unique to mycobacteria to ensure that DNA of other organisms is not amplified along with the mycobacterial DNA. The primer binding sequences also shall be highly conserved among all mycobacterial species that need to be detected. If the primer binding sequences are not well-conserved, certain mycobacterial species with substantially divergent sequences might not get amplified.

10.2.1 Several primer pairs may be used to enhance specificity. Each primer pair can simultaneously amplify a different target sequence within the mycobacterial genome. Alternatively, one target sequence can be amplified using a single primer set to generate an initial amplification product. Then, a second set of nested primers, which recognize sequences within the initial amplification product, can be used to generate the shorter, final amplification product (see 10.2.1.2).

10.2.1.1 *Multiple Targets*—The likelihood of false-positive results is reduced by defining a positive result as the presence of multiple, specific amplification products. Reactions inadvertently contaminated with a single DNA target sequence will contain only a single amplified target and not be classified as positive. Reactions containing non-specifically amplified DNA that mimics one of the target sequences will lack the other specific targets and not be classified as positive.

10.2.1.2 *Nested Amplification*—The primary target is amplified using an outer set of primers to generate an intermediate that serves as the target for the second set of internal primers. This two-stage amplification process can generate more final product, thereby increasing analytical sensitivity. Specificity will be enhanced, because the final amplification product will be formed only if the correct intermediate is formed. Products formed by non-specific interactions between the first set of primers and extraneous DNA will not contain binding sites for the second set of primers and, thus, will not generate the characteristic final product. Caution should be taken when using nested PCR, according to the general PCR Guide E 1873.

10.2.2 The target sequence recognized by the primers may

be present in a single copy in the mycobacterial genome or may be present in multiple copies. Because they are present in multiple copies in each organism, repetitive target sequences provide a natural amplification that may enhance the analytical sensitivity of the assay.

10.2.3 The primer binding sequences may be specific to one species of mycobacteria or may be conserved among several species of mycobacteria. Species-specific primers should be used when the assay is required to detect only one species of mycobacteria. Primers that are conserved among several species should be used for applications where it is desirable to detect any, or all, of the different species of mycobacteria that may be present in a sample. An example of the latter application is clinical diagnosis. Specimens from patients suspected of having mycobacteria infection may contain any one of several pathogenic species. A diagnostic test shall be able to detect all of the species and identify which of them is actually present.

10.2.3.1 *Species-Specific Primers*—The sequences recognized by these primers shall be unique to the species of interest and shall not be found in other mycobacterial species. Table 1 lists several species-specific primers for the amplification of the MTBC.

10.2.3.2 *Multiple Species Primers*—These primers should contain sequences that are conserved in all of the mycobacterial species of interest. If it will be necessary to identify the particular species present in a sample, the primers should be positioned so that a portion of the sequence between them differs among the target species. A set of species-specific probes that are homologous to this unique region can be hybridized to the amplified DNA for species identification. Table 1 lists several primer pairs that amplify DNA from multiple mycobacterial species and yield products that can contain unique sequences for species identification.

10.3 *Detection of Amplification Products*—The method used to visualize reaction products shall distinguish amplified target DNA from DNA generated from non-specific interactions between primers or between primers and non-target DNA.

10.3.1 For amplification products generated by species-specific primers, gel electrophoresis can be used to demonstrate that the product matches the expected size of the amplified target DNA. Alternatively, more specific detection techniques, such as restriction enzyme digestion or hybridization to a DNA probe, can be used to show that the products contain sequences characteristic of amplified target DNA and should be used in clinical laboratory practice.

10.3.2 Amplification products generated by primers that interact with multiple species may be detected using generic techniques that do not identify the individual species present, or they may be visualized using species-specific detection methods. Generic detection techniques can be used to screen for specimens that contain mycobacteria. This can be accomplished by gel electrophoresis or by using probes or restriction enzymes that recognize sequences conserved among all the target species. Species-specific detection techniques can then be used to identify the target organism(s) present in each of the



specimens identified as positive by a generic detection method.  
DNA probes for variable sequences that differ among the target  
species are required for this purpose.

**TABLE 1 Primers and Probes for PCR Amplification of Mycobacterial DNA**

Target Gene	Function	Specificity	Name	Sequence	Reference
65 kD protein	upstream primer	genus	TB-1	5'GAGATCGAGCTGGAGGATCC3'	(29)
	downstream primer	genus	TB-2	5'AGCTGCAGCCCAAAGGTGT3'	(30)
	upstream primer	<i>M. tuberculosis</i>	TB-28	5'CCATCGATCCGAGACCCTGCTCAAGGGC3'	
	downstream primer	<i>M. tuberculosis</i>	TB-29	5'TGCTCTAGACTCCTCGACGGTGATGACG3'	
	probe	<i>M. tuberculosis</i>	TB-3	5'GCGGCATCGAAAAGGCCGTG3'	
	probe	<i>M. tuberculosis</i>	TB-4	5'CGAAATCGCTGCGGTGGCCG3'	
	probe	<i>M. avium</i>	TB-5	5'CTGCCACCGCGGCCATCTCC3'	
	probe	<i>M. fortuitum</i>	TB-6	5'CTGCCACCGCGGTATCTCC3'	
16S rRNA	upstream primer	genus	KY18	5'CACATGCAAGTCGAACGGAAAGG3'	(31)
	downstream primer	genus	KY75	5'GCCCGTATCGCCCGACGCTCAC3'	
	probe	<i>M. tuberculosis</i>	KY172T3	5'GGTGAAAGCGCTTTAGCGGT3'	
	probe	<i>M. avium</i>		proprietary <sup>A</sup>	
	probe	<i>M. intracellulare</i>		proprietary <sup>A</sup>	
16S rRNA	upstream primer	slow growing mycobacteria	MYCOB	5'ATGCAAGTCGAACGGAAGG3'	(32)
	downstream primer	slow growing mycobacteria		5'TGCACACAGGCCACAAGGA3'	
	upstream primer	<i>M. avium</i>	MAV	5'CCTCAAGACGCATGTCTTCT3'	
	downstream primer	<i>M. avium</i>		5'ACAGCTCCCTCCCAAAGGG3'	
	upstream primer	<i>M. intracellulare</i>	MIN	5'CCTTTAGGCGCATGTCTTTA3'	
	downstream primer	<i>M. intracellulare</i>		5'GCACAGCTCCCTCCCAAGGG3'	
	probe			none used	
16S rRNA	upstream primer	genus	246	5'AGAGTTTGATCTGGCTCAG3'	(33)
	downstream primer	genus	264	5'TGCACACAGGCCACAAGGA3'	
	downstream primer	genus	260	5'GTCTGTGCATGTCAAACCC3'	
	downstream primer	genus	267	5'CACGCCCACAGTTAAGCTGT3'	
	probe	genus	247	5'TTTCACGAACAACGCGACAA3'	
	probe	<i>M. tuberculosis</i>		5'ACCACAAGACATGCATCCCG3'	
	probe	<i>M. avium/paratb</i>		5'ACCAGAAGACATGCGTCTTG3'	
	probe	<i>M. intracellulare</i>		5'ACCTAAAGACATGCGCCTAA3'	
Superoxide dismutase	upstream primer	universal (all organisms)	Z205	5'AGCTTCACCACAGCAAGCACCA3'	(34)
	downstream primer	universal	Z212	5'TCG(G,T)CCCAGTTCACGAC(G,A)TTCCA3' <sup>B</sup>	
	upstream primer	genus	Z261	5'CCAA(A,G)CTCGAAGAGGCGCG(C,G)GCCAA3' <sup>B</sup>	
	probes: cocktail for genus detection	<i>M. tuberculosis</i>	Z310	5'GACAAGCCACCGGCGAACTCGCCGCGAGCCATCGCCG3'	
		<i>M. xenopi</i> and <i>M. intracellulare</i>	Z311	5'GACAAGCCGACCGGCGAATTGGCCGCCGC(G,C)ATCGACG3' <sup>B</sup>	
		<i>M. avium</i>	Z312	5'GACAAGCCACCGGTGAGCTGGCCGCCGCGATCGACG3'	
		<i>M. gordonae</i>	Z313	5'GACAAGCCGACCGGTGACCTGGCCGCCGCGATCGACG3'	
		<i>M. fortuitum</i>	Z314	5'GACAAGCCGACCGGCGATCTGGCCGCCGCGATCGAC3'	
		<i>M. scrofulaceum</i>	Z315	5'GACAAGCCGACCGGAGAAGTGGCCGCCGCGATCGATG3'	
		<i>M. simiae</i>	Z316	5'GACAAGCCGACCGGAGATCTGCCGCCGCCATCGACG3'	
		<i>M. kansasii</i>	Z317	5'GACAAGCCGACCGGCGAACTCGCCGCCGCCATCGACG3'	
	probes for species detection	<i>M. tuberculosis</i>	Z302	5'ACGAACCTCCCGCTAGGCATTGTTCCGCTGCTGCTGC3'	
		<i>M. tuberculosis</i>	Z337	5'AGTCGACTTTGCCAAGGCGTTT3'	
		<i>M. avium</i>	Z301	5'GTCTTCGACAAGTTCCGAGCGCAATTCAGCGCCGCC3'	
		<i>M. intracellulare</i>	Z303	5'CCTTCGGATCCTTCGACCGGTTCCGCGCGCAGTTCAG3'	
	probes for species detection	<i>M. scrofulaceum</i>	Z306	5'TGACACACTCGGCAGCAGGCTGCTCACCTTCAGCTT3'	
		<i>M. kansasii</i>	Z340	5'CCAGACGAACCTTCCACTCGGA3'	
		<i>M. fortuitum</i>	Z369	5'ACGACAGCCTGGGCGATCGGCT3'	
		<i>M. simiae</i>	Z304	5'GTCCCGAAGCGCGGAGACAAGCCGACCGGAGATCTC3'	
		<i>M. gordonae</i>	Z366	5'TCTGGGCGGCGGTTGCTCACCTTT3'	
		<i>M. xenopi</i>	Z309	5'TCCGCGATCGTCGGGCATGAGAAGGCCCTCGCGTTCA3'	
Repetitive element	upstream primer	genus	MtbA	5'GGGTGCGGTGACTCCGGGGGCT3'	(35)
	downstream primer	genus	MtbB	5'CGGTGGGAACGGGGGCT3'	
	upstream primer	genus	MtbC	5'TACGGATTCCGTCCACCGTCAT3'	
	downstream primer	genus	MtbD	5'CACCGGCGGAACACT3'	
	probe	<i>M. tuberculosis</i>	none	PCR products derived from amplification of <i>M. tuberculosis</i> DNA	
IS6110	upstream primer	<i>M. tuberculosis</i> complex	IS41	5'CCTGCGAGCGTAGGCGTCGG3'	(36)

TABLE 1 Continued

Target Gene	Function	Specificity	Name	Sequence	Reference
	downstream primer	<i>M. tuberculosis</i> complex	IS43	5'TCAGCCGCGTCCACGCCGCCA3'	(37)
	downstream primer	<i>M. tuberculosis</i> complex		5'CTCGTCCAGCGCCGCTTCGG3'	
	probe		none	PCR products derived from amplification of <i>M. tuberculosis</i> DNA	
MPB64 protein	upstream primer	<i>M. tuberculosis</i> complex	1	5'TCCGCTGCCAGTCGTCTTCC3'	(38)
	downstream primer	<i>M. tuberculosis</i> complex	2	5'GTCCTCGCGAGTCTAGGCCA3'	
	probe	<i>M. tuberculosis</i> complex		5'CTTCAACCCGGGGGAGT3'	
Clone pPH7301	upstream primer	<i>M. tuberculosis</i> complex	A	5'GGTCCTGACGGTAATGGGGT3'	(6)
	downstream primer	<i>M. tuberculosis</i> complex	D	5'CGCCCATCCACATCCCGCCC3'	
	probe	<i>M. tuberculosis</i> complex	E	5'GGACATCTCTGTTCCATCCA3'	
38kD protein	upstream primer	<i>M. tuberculosis</i> complex	MT1	5'ACCACCGAGCGGTTGCGCTGA3'	(39)
	downstream primer	<i>M. tuberculosis</i> complex	MT2	5'GATCTGCGGGTCGTCCCAGGT3'	
	probe	<i>M. tuberculosis</i> complex	MT3	5'CGCTGTTCAACCTGTGGGGTCCGGCCTTTC3'	
Repetitive element	upstream primer	<i>M. tuberculosis</i> complex		5'GCGGCTCGGGCGGCGTCGGTGGCTT3'	(40)
	downstream primer	<i>M. tuberculosis</i> complex		5'GCCAGAACCACCAACCCGCCGATA3'	
	probe	<i>M. tuberculosis</i> complex		cloned DNA	
MBP70 antigen	upstream primer	<i>M. tuberculosis</i> complex	TB1A	5'GAACAATCCGGAGTTGACAA3'	(20)
	downstream primer	<i>M. tuberculosis</i> complex	TB1B	5'AGCACGCTGTCAATCATGTA3'	
	probe			none	
18kD protein	upstream primer	<i>M. leprae</i>		5'ATTCGTCGTCGAGTTCGACCTTCT3'	(16)
	downstream primer	<i>M. leprae</i>		5'TGACAACAAACGCGTTGTCGATTCT3'	
	probe			cloned DNA	

<sup>A</sup>Probes are available commercially in the COBAS AMPLICOR and AMPLICOR *Mycobacterium avium* and *Mycobacterium intracellulare* detection kits.

<sup>B</sup>Primer or probe is a mixture of multiple sequences. Parentheses indicate positions of sequence heterogeneity. Each oligonucleotide in the mixture contains one of the two nucleotides shown in each set of parentheses (for example, if there are two sets of parenthesis, mixture is composed of four distinct sequences).

## 11. Conditions Preliminary to the Performance of PCR

11.1 *General*—See recommendations of Guide E 1873 (Section 10).

## 12. Performance of PCR

12.1 *General*—See recommendations of Guide E 1873 (Section 11). Additional details on the design and utilization of internal controls can be found in Ref. (28).

12.2 The positive control(s) used should be added sufficiently early in order to control the course of the entire process from extraction of nucleic acids to detection of the amplified products.

## 13. Evaluation and Interpretation of Results

13.1 *General*—See Guide E 1873 (Section 12).

13.2 In addition to the above, for clinical, in vitro diagnostic PCR testing, the nucleic acid detection of the MTBC is to be evaluated as:

13.2.1 *Positive*—A signal obtained by hybridization was above the cut-off value taken as baseline for the procedure in

comparison with the accompanying controls, or a specific amplified product obtained and characterized by means of its sequence or its restriction fragment pattern or its molecular weight, or a combination thereof.

13.2.2 *Negative*—In the case of hybridization, signal did not exceed a cut-off value taken as baseline for the procedure, or a specific amplified product was not obtained when consideration was given to the result of the accompanying controls.

13.2.3 *Indeterminate*—The positive or negative control reactions did not work correctly, or the internal control indicated an amplification failure due to either inhibition by the sample or technical error. Under these conditions the test is to be repeated with consideration given to the problem that occurred.

13.2.4 *Inconclusive*—In the case of hybridization, a test result was obtained that lies in a narrow region close to the threshold value, or a specific amplified product could not be generated in sufficient amount. Inconclusive results are to be repeated in the same laboratory and an attempt made to obtain an interpretable result.

13.3 Evaluation and documentation of the amplified product

should be carried out.

13.4 Interpretation of results of the PCR reaction depends on: 1) what results were obtained with the controls, 2) which primers were used for the amplification, 3) which target sequences were used, 4) which test procedure was used for obtaining the amplified product, 5) whether DNA or RNA was used as starting material, and 6) from which test specimens the mycobacteria were obtained and concentrated.

## 14. Report

14.1 General requirements for the report are given in Guide E 1873 (Section 13).

14.2 For a report of in vitro diagnostic PCR test results, in order to assure a correct diagnosis:

14.2.1 A report of positive findings may include a recommendation that a repeat of the test may be made using fresh test material when a patient has a positive nucleic acid detection for the first time. The recommendation should take into consideration the results of other test procedures such as microscopy and culture.

14.2.2 A report of negative findings is generated in the case of a validated, negative test result. A negative nucleic acid detection report should always contain an addendum that states even in the case of a negative result, an infection with mycobacteria is not completely excluded. When tuberculosis continues to be suspected, a recommendation is to be included in the report concerning a suitable time for a test repeat and the type of test specimens.

14.2.3 A report of questionable findings should be made only in the case that after repeated, unclear results have been

obtained, the existence or absence of the suspected mycobacteria cannot be eliminated or verified. The performance of further tests with newly obtained test specimens should be recommended.

14.2.4 In all cases described in 14.2.1-14.2.3, the report should comment upon the validity of all associated diagnostic methods utilized. The report should also take into consideration any other test procedures used such as microscopy and culture available at that time.

## 15. Quality Assurance

15.1 Basic concepts for quality assurance in the laboratory should be followed, according to NCCLS C24-A and NCCLS MM3-A.

15.2 See the general requirements given in Guide E 1873 (Section 14).

15.3 In addition to 15.2, the user should keep in mind that the detection of mycobacterial nucleic acids by PCR is a rapidly developing area, and the user needs to consider current innovations in the field and to integrate them into the test methodology and report interpretation.

## 16. Troubleshooting

16.1 See Guide E 1873 (Section 15).

## 17. Keywords

17.1 amplification; DNA primer; DNA probe; *M. avium*; *M. intercellulare*; MTB; MTB complex; *Mycobacterium tuberculosis*; PCR; polymerase chain reaction; TB; tuberculosis

## REFERENCES

- (1) Crofton, J., Chaulet, P., and Maher, D., "Guidelines for the Management of Drug-Resistant Tuberculosis," *World Health Organization*, Geneva, 1997.
- (2) Rattan, A., Kalia, A., and Ahmad, N., "Multidrug-Resistant *Mycobacterium tuberculosis*: Molecular Perspectives," *Emerging Infectious Diseases*, Vol 4, 1998, pp. 195-209.
- (3) Richmond, J.Y., and McKinney, R.W., *Biosafety in Microbiological and Biomedical Laboratories*, 3<sup>rd</sup> ed., U.S. Department of Health and Human Services, Publication No. (CDC) 93-8395, U.S. Government Printing Office, Washington DC, 1993.
- (4) Sepkowitz, K.A., Raffalli, J., Riley, L., Kiehn, T.E., and Armstrong, D., "Tuberculosis in the AIDS Era," *Clinical Microbiology Reviews*, Vol 8, 1995, pp. 180-199.
- (5) Daniel, T. M., "The Rapid Diagnosis of Tuberculosis: A Selective Review," *Journal of Laboratory Clinical Medicine*, Vol 116, 1990, pp. 277-282.
- (6) Hermans, P.W.M., Schuitema, A.R.J., and Soolingen, D.V., "Specific Detection of *Mycobacterium tuberculosis* Complex Strains by Polymerase Chain Reaction," *Journal of Clinical Microbiology*, Vol 28, 1990, pp. 1204-1213.
- (7) Huang, C.H. and Jungkind, D.L., "Non-Radioactive Probe for the Rapid Identification of *Mycobacterium avium* Complex from Clinical Specimens," *Molecular and Cellular Probes*, Vol 5, 1991, pp. 277-280.
- (8) Nolte, F.S. and Metchock, B., "Mycobacterium," *Manual of Clinical Microbiology*, 6th ed., American Society for Microbiology Press, Washington, DC, 1995, pp. 400-437.
- (9) Frothingham, R. and Wilson, K.H., "Molecular Phylogeny of the *Mycobacterium avium* Complex Demonstrates Clinically Meaningful Divisions," *Journal of Infectious Diseases*, Vol 169, 1994, pp. 305-312.
- (10) Thorel, M.F., Krichevsky, M., and Levy-Frebault, V., "Numerical Taxonomy of Mycobactin-Dependent Mycobacteria, Emended Description of *Mycobacterium avium*, and Description of *Mycobacterium avium* Subsp. *avium* subsp. Nov., *Mycobacterium avium* Subsp. *Paratuberculosis* Subsp. Nov., and *Mycobacterium avium* Subsp. *Silvaticum* Subsp. Nov.," *International Journal of Systematic Bacteriology*, Vol 40, 1990, pp. 254-260.
- (11) Wayne, L., and Sramek, H., "Agents of Newly Recognized or Infrequently Encountered Mycobacterial Diseases," *Clinical Microbiology Reviews*, Vol 5, 1992, pp. 1-25.
- (12) Von Reyn, C.F., Waddell, R.D., Eaton, T., Arbeit, R. D., Maslow, J. N., Barber, T. W., Brindle, R. J., Gilks, C. F., Lumio, J., Lahdevirta, J., Ranki, A., Dawson, D., and Falkinham III, J. O., "Isolation of *Mycobacterium avium* complex from Water in the United States, Finland, Zaire, and Kenya," *Journal of Clinical Microbiology*, Vol 31, 1993, pp. 3227-3230.
- (13) Horsburgh, C.R., "Advances in the Prevention and Treatment of *Mycobacterium avium* Disease," *New England Journal of Medicine*, Vol 335, 1996, p. 428.
- (14) Guthertz, L.S., Damsker, B., Bottone, E.J., Ford, E.G., Midura, T.D., and Janda, J.M., "*Mycobacterium avium* and *Mycobacterium intracellulare* Infections in Patients With and Without AIDS," *Journal of Infectious Diseases*, Vol 160, 1989, pp. 1037-1041.

- (15) Inderlied, C.B., Kemper, C.A., and Bermudez, L.E.M., "The *Mycobacterium avium* Complex," *Clinical Microbiology Reviews*, Vol 6, 1993, pp. 266-310.
- (16) Williams, D. L., Gillis, T.P., Booth, R.J., Looker, D., Watson, J.D., "The Use of a Specific DNA Probe and Polymerase Chain Reaction for the Detection of *Mycobacterium leprae*," *Journal of Infectious Diseases*, Vol 162, 1990, pp. 193-200.
- (17) Young, K.K.Y., "The Detection of Mycobacterial DNA Using PCR," *PCR-Based Diagnostics in Infectious Disease*, Blackwell Scientific Publications, Inc., Boston, MA, 1994, pp. 537-558.
- (18) Beavis, K., Lichty, M.B., and Jungkind, D.L., "Evaluation of Ampli-cor PCR for Direct Detection of *Mycobacterium tuberculosis* from Sputum Specimens," *Journal of Clinical Microbiology*, Vol 33, 1995, pp. 2582-2586.
- (19) Bodmer, T., Gurtner, A., Scholkmann, M., and Matter, L., "Evaluation of the COBAS AMPLICOR MTB System," *Journal of Clinical Microbiology*, Vol 35, 1997, pp. 1604-1605.
- (20) Cousins, D.V., Wilton, S.D., and Francis, B.R., "Use of Polymerase Chain Reaction for Rapid Diagnosis of Tuberculosis," *Journal of Clinical Microbiology*, Vol 30, 1992, pp. 255-258.
- (21) Piersimoni, C., Callegaro, A., Nista, D., Bornigia, S., DeConti, F., Santini, G., and De Sio, G., "Comparative Evaluation of Two Commercial Amplification Assays for the Direct Detection of *Mycobacterium tuberculosis* Complex in Respiratory Samples," *Journal of Clinical Microbiology*, Vol 35, 1997, pp. 193-196.
- (22) Yuen, K-Y., Yam, W-C., Wong, L-P., and Seto, W-H., "Comparison of Two Automated DNA Amplification Systems with a Manual One-Tube Nested PCR Assay for Diagnosis of Pulmonary Tuberculosis," *Journal of Clinical Microbiology*, Vol 35, 1997, pp. 1385-1389.
- (23) Gamboa, F., Manterola, J. M., Lonca, J., Matas, L., Viñado, B., Giménez, M., Cardona, P. J., Padilla, E., and Ausina, V., "Detection and Identification of Mycobacteria by Amplification of RNA and DNA in Pretreated Blood and Bone Marrow Aspirates by a Simple Lysis Method," *Journal of Clinical Microbiology*, Vol 35, 1997, pp. 2124-2128.
- (24) Ichiyama, S., Iinuma, Y., Tawada, Y., Yamori, S., Hasegawa, Y., Shimokata, K., and Nakashima, N., "Evaluation of Gen-Probe Amplified *Mycobacterium tuberculosis* Direct Test and Roche PCR-Microwell Plate Hybridization Method (AMPLICOR *Mycobacterium*) for Direct Detection of Mycobacteria," *Journal of Clinical Microbiology*, Vol 34, 1996, pp. 130-133.
- (25) Kox, L.F., van Leeuwen, J., Knijper, S., Jansen, H.M., and Kolk, A.H., "PCR Assay Based on DNA Coding for 16S rRNA for Detection and Identification of Mycobacteria in Clinical Samples," *Journal of Clinical Microbiology*, Vol 33, 1995, pp. 3225-3233.
- (26) Oggioni, M.R., Fattorini, L., Li, B., De Milito, A., Zazzi, M., Pozzi, G., Orefici, G., and Valensin, P.E., "Identification of *Mycobacterium tuberculosis* Complex, *Mycobacterium avium* and *Mycobacterium intracellulare* by Selective Nested Polymerase Chain Reaction," *Molecular and Cellular Probes*, Vol 9, 1995, pp. 321-326.
- (27) Yanazaki, T. and Nakamura, R.M., "Identification of *Mycobacterium intracellulare* by a Polymerase Chain Reaction Using Species-Specific Primers," *Tuberculosis Lung Disease*, Vol 76, 1995, pp. 330-335.
- (28) Rosenstrauss, M., Wang, Z., Chang, S.-Y., DeBonville, D., and Spadaro, J.P., "An Internal Control for Routine Diagnostic PCR: Design, Properties, and Effect on Clinical Performance," *Journal of Clinical Microbiology*, Vol 36, 1998, pp. 191-197.
- (29) Hance, A.J., Grandchamp, B., Lévy-Frébault, V., Lecossier, D., Raugier, J., Bocart, D., and Gicquel, B., "Detection and Identification of Mycobacteria by Amplification of Mycobacterial DNA," *Molecular Microbiology*, Vol 3, 1989, pp. 843-849.
- (30) Pierre, C., Lecossier, D., Boussougant, Y., Bocart, D., Joly, V., Yeni, P., and Hance, A.J., "Use of a Reamplification Protocol Improves Sensitivity of Detection of *Mycobacterium tuberculosis* in Clinical Samples by Amplification of DNA," *Journal of Clinical Microbiology*, Vol 29, 1991, pp. 712-717.
- (31) Tevere, V. J., Hewitt, P. L., Dare, A., Hocknell, P., Keen, A., Spadaro, J. P., and Young, K. K. Y., "Detection of *Mycobacterium tuberculosis* by PCR Amplification with Pan-*Mycobacterium* Primers and Hybridization to an *M. tuberculosis*-Specific Probe," *Journal of Clinical Microbiology*, Vol 34, 1996, pp. 918-923.
- (32) Chen, Z.H., Butler, W.R., Baumstark, B.R., and Ahearn, D.G., "Identification and Differentiation of *Mycobacterium avium* and *M. intracellulare* by PCR," *Journal of Clinical Microbiology*, Vol 34, 1996, pp. 1267-1269.
- (33) Boddington, B., Rogall, T., Flohr, T., Blocker, H., and Bottger, E.C., "Detection and Identification of Mycobacteria by Amplification of rRNA," *Journal of Clinical Microbiology*, Vol 28, 1990, pp. 1751-1759.
- (34) Zolg, J. W., and Philippi-Schulz, S., "The Superoxide Dismutase Gene, a Target for Detection and Identification of Mycobacteria by PCR," *Journal of Clinical Microbiology*, Vol 32, 1994, pp. 2801-2812.
- (35) Patel, R. J., Fries, J. W., Piessens, W. F., and Wirth, D. F., "Sequence Analysis and Amplification by Polymerase Chain Reaction of a Cloned DNA Fragment for Identification of *Mycobacterium tuberculosis*," *Journal of Clinical Microbiology*, Vol 28, 1990, pp. 513-518.
- (36) Eisenach, K. D., Cave, M. D., Bates, J. H., and Crawford, J. T., "Polymerase Chain Reaction Amplification of a Repetitive DNA Sequence Specific for *Mycobacterium tuberculosis*," *Journal of Infectious Diseases*, Vol 161, 1990, pp. 977-981.
- (37) Plikaytis, B.B., Eisenach, K.D., Crawford, J.T., and Shinnick, T.M., "Differentiation of *Mycobacterium tuberculosis* and *Mycobacterium bovis* BCG by a Polymerase Chain Reaction Assay," *Molecular and Cellular Probes*, Vol 5, 1991, pp. 215-219.
- (38) Shankar, P., Manjunath, N., Lakshmi, R., Aditi, B., Seth, P., and Shriniwas, M.D., "Identification of *Mycobacterium tuberculosis* by Polymerase Chain Reaction," *Lancet*, Vol 335, 1990, p. 423.
- (39) Sjobring, U., Mecklenburg, M., Andersen, A.B., and Miorner, H., "Polymerase Chain Reaction for Detection of *Mycobacterium tuberculosis*," *Journal of Clinical Microbiology*, Vol 28, 1990, pp. 2200-2204.
- (40) De Wit, D., Steyn, L., Shoemaker, S., and Sogin, M., "Direct Detection of *Mycobacterium tuberculosis* in Clinical Specimens by DNA Amplification," *Journal of Clinical Microbiology*, Vol 28, 1990, pp. 2437-2441.

The American Society for Testing and Materials takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.

This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.

This standard is copyrighted by ASTM, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or service@astm.org (e-mail); or through the ASTM website (www.astm.org).